R. Scott McClelland, MD, MPH | Allergy and Infectious Diseases

Professor

Department of Epidemiology

Professor

Department of Global Health

Faculty Information

Biography

Dr. McClelland is a Professor of Medicine, Epidemiology, and Global Health. He is Director of the UW School of Medicine Global Health Clinical Elective Program. Dr. McClelland is also co-Director of UW Kenya Research and Training Center and Associate Director of the UW Center for AIDS Research (CFAR) International Core. As Site Leader for the UW/University of Nairobi (UON) Mombasa HIV & STD Research Site, Dr. McClelland directs strong collaborative research efforts between the UW, UON, the Kenya Medical Research Institute (KEMRI), Coast General Hospital, Mombasa County, Kenya's National AIDS and STD Control Programme, and the Kenya Ministry of Health.

Dr. McClelland is a clinical attending on the Internal Medicine and Infectious Diseases Consult services at Harborview Medical Center. He also teaches Epidemiology 532, "Epidemiology of Infectious Diseases in Resource-Limited Countries." The course is offered every other year (odd number years) in the Spring. Dr. McClelland is a regular lecturer in med 561 (Tropical Medicine), EPI 507/OBGYN590 (HIV and STDs in Women and Children), EPI 530 (AIDS, A Multidisciplinary Approach), and GH573 (Clinical Management of HIV), GH560 (Principles of STD and HIV Research).

Education & Training:

University of Washington

Seattle, WA

1995

MPH

University of Washington

Seattle WA

2001

Residency

Duke University Medical Center

Durham, NC

1995-1998

Fellowship in Infectious Diseases

University of Washington

Seattle WA

1998-2002

Honors:

Phi Beta Kappa

1990

Alpha Omega Alpha Honor Medical Society

1994

Infectious Disease Society of Obstetrics and Gynecology Top Abstract Award

2014

University of Washington, Department of Medicine, Mentor of the Year Award

2015

Contact

Email:

mcclell@uw.edu

Phone:

(206) 543-4278

Mailing Address:

325 9th Avenue
Box 359909
Seattle, WA 98104-2499

Research & Clinical Interests

Research Interests:

Dr. McClelland's research focuses on human immunodeficiency virus (HIV) and sexually transmitted infection (STI) epidemiology and prevention in key populations including female sex workers, HIV-discordant couples, pregnant women, and men who have sex with men. This includes both primary prevention strategies for reducing the risk of HIV/STI acquisition and secondary prevention aimed at reducing infectiousness and risk behavior.

A current NIH/NICHD funded R01 grant titled, "Women's Lifecourse Events & HIV Transmission Potential: A Multidisciplinary Study," is ongoing Mombasa and Nairobi. This study explores transmission potential in HIV-positive women on antiretroviral therapy in relation to key lifecourse events including marriage, decisions about contraception, conception, pregnancy, the post-partum period, menopause, depression, alcohol use, and intimate partner violence.

Another study involving HIV-positive women will be starting in the second half of 2015. This NIH/NIMH funded R21 entitled, "Motivation Matters! RCT of theory-based, 2-way SMS to support TASP in African FSW," will develop and test an SMS intervention grounded in the theory of Information, Motivation, and Behavioral Skills as a method for supporting antiretroviral adherence and viral load suppression in HIV-positive sex workers initiating treatment as prevention.

Dr. McClelland was Protocol Chair for a recently completed Sexually Transmitted Infections Clinical Trials Group funded study titled, "Preventing Vaginal Infections (PVI Trial)." This trial demonstrated the efficacy of periodic presumptive treatment with metronidazole and miconazole for reducing the incidence of bacterial vaginosis in the intervention arm compared to controls. Ancillary analyses with the dataset have demonstrated trends for decreases in Neisseria gonorrhoeae, Chlamydia trachomatis, and Mycoplasma genitalium. Planning for a Phase III trial of the PVI intervention to test the hypothesis that reducing BV is an effective method for reducing bacterial STIs are at an early stage. A linked R01 is supporting molecular microbiological testing of archived specimens from the PVI trial, and analyses of these data are ongoing.

Publications

PubMed:

PubMed Bibliography

Publications:

McClelland RS, Balkus JE, Lee J, Anzala O, Kimani J, Schwebke J, Bragg V, Lensing S, Kavak L. Randomized trial of periodic presumptive treatment with high-dose intravaginal metronidazole and miconazole to prevent vaginal infections in HIV-negative women. J Infect Dis. 2015; 211:1875-82.
• PubMed Abstract

Day S, Graham SM, Masese LN, Richardson BA, Kiarie JN, Jaoko W, Mandaliya K, Chohan V, Overbaugh J, McClelland RS. A prospective cohort study of the effect of depot medroxyprogesterone acetate on detection of plasma and cervical HIV-1 in women initiating and continuing antiretroviral therapy. J Acquir Immun Defic Syndr. 2014; 66:452-456.
• PubMed Abstract.

McClelland RS, Graham SM, Richardson BA, et al. Treatment with antiretroviral therapy is not associated with increased sexual risk behavior in Kenyan female sex workers. AIDS. 2010; 24(6): 891-7.
• PubMed Abstract

McClelland RS, Richardson BA, Hassan WM, et al. Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial. J Infect Dis. 2008; 197:1361-8.
• PubMed Abstract

McClelland RS, Sangaré L, Hassan WM, Lavreys, L, Mandaliya K, Kiarie J, et al. Infection with Trichomonas vaginalis increases the risk for HIV-1 acquisition. J Infect Dis. 2007; 195:698-702.
• PubMed Abstract

McClelland RS, Lavreys L, Hassan WM, Mandaliya K, Ndinya-Achola JO, Baeten JM. Vaginal washing and increased risk of HIV-1 acquisition among African women: A 10-year prospective study. AIDS. 2006; 20:269-73.
• PubMed Abstract